Document is current

Article History

Received: 1 November 2022

Accepted: 27 July 2023

First Online: 1 August 2023

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was grantedby the research ethics committee of Showa University Northern Yokohama Hospital (31 June 2018; approval number:17H097).

: was obtained from all individual participants included in the study.

: Informed consent was obtained from all individual participants included in the study.

: Dr. Takeo Nakayama reports personal fees from Pfizer Japan Inc., MSD K.K., Ohtsuka Pharmaceutical Co., Chugai Pharmaceutical Co., Dentsu Co., Takeda Pharmaceutical Co., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Baxter, Alexion, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Allergan Japan K.K., Maruho Co., Ltd.; research grants from HANSHIN Dispensing Holding Co., Ltd., Nakagawa Pharmacy Co., Ltd., Konica Minolta, Inc. All of them were outside the submitted work. Dr. Shuichi Nawata reports personal fees from Chugai Pharmaceutical Co., Taiho Pharmaceutical Co., Ltd; readership of Japanese Society of Pharmaceutical Oncology., Japan Society of Clinical Oncology., Japanese Society of Medical Oncology., Japanese Society of Pharmaceutical Health Care and Sciences.